| Identification | Back Directory | [Name]
5-(2,4-DiaMino-pyriMidin-5-yloxy)-4-isopropyl-2-Methoxy-benzenesulfonaMide | [CAS]
1015787-98-0 | [Synonyms]
MK7264
MK-7264
CS-2846
MK 7264
EOS-6104
EOS-61047
Gefapixant
RO-4926219
Gefapixant(AF-219
Gefapixant(AF-219,MK-7264)
GEFAPIXANT;AF-219;MK-7264;AF 219;MK 7264;AF219;MK7264
5-(2,4-DiaMino-pyriMidin-5-yloxy)-4-isopropyl-2-Methoxy-benzenesulfonaMide
5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)Benzenesulfonamide
Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-
GEFAPIXANT; MK-7264; MK 7264; MK7264; AF-219; AF219; AF 219; RO4926219; RO-4926219; RO 4926219; | [Molecular Formula]
C14H19N5O4S | [MDL Number]
MFCD24539325 | [MOL File]
1015787-98-0.mol | [Molecular Weight]
353.4 |
| Chemical Properties | Back Directory | [Boiling point ]
606.3±65.0 °C(Predicted) | [density ]
1.391±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:38.0(Max Conc. mg/mL);107.53(Max Conc. mM) | [pka]
9.90±0.60(Predicted) |
| Hazard Information | Back Directory | [Description]
Gefapixant was approved in Japan in 2022 for adult patients with refractory or unexplained chronic cough, marketed under the name Lyfnua.The drug was authorised by the European Medicines Agency (EMA) in September 2023 for the same indication. However, the FDA refused to approve gefapixant for the treatment of adults with refractory or unexplained chronic cough. | [Uses]
Gefapixant is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant can be used for the research of chronic cough and knee osteoarthritis. |
|
|